APOE and Alzheimer disease: For example, there is higher AD risk in female APOE4 carriers, compared to male APOE4 carriers (Farrer et al., 1997; Altmann et al., 2014), which may be pronounced at older ages (65–75 years of age) (Neu et al., 2017).